Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06028334

GetUp&Go: A Randomized Controlled Trial of an Intervention to Enhance Physical Activity After TBI

The goal of this clinical trial is to evaluate GetUp&Go, a program for promoting increased physical activity in individuals at least 6 months post moderate-to-severe traumatic brain injury. GetUp&Go is a remotely delivered 10-week program that includes one-on-one sessions with a therapist and a mobile health application (RehaBot).

The main question is whether participants in the 10-week GetUp&Go program increase their physical activity, and exhibit associated benefits in mental and physical health, relative to those who are put on a waitlist.

* Question 1: Do participants who receive immediate treatment with GetUp&Go show more increased physical activity, measured by accelerometer activity counts per day, and improve more on secondary outcomes, such as self-reported physical activity, emotional function, fatigue, sleep, pain, and health-related quality of life, compared to their baseline, relative to those who are put on a waitlist? * Question 2: Do participants who have continued access to the mobile health component of the intervention, RehaBot, show better maintenance of physical activity gains compared to those who no longer have access to RehaBot? * Question 3: Are individual participant characteristics associated with participants' response to the treatment program?

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Moss Rehabilitation Research Institute

Elkins Park, Pennsylvania, 19027, United States

Location status: Recruiting

Location contact

Amanda Rabinowitz, PhD

PRINCIPAL_INVESTIGATOR

About this study

The investigators will conduct a Randomized Controlled Trial (RCT) of a novel, remotely delivered physical activity (PA) promotion program, called GetUp&Go-a name selected by focus group participants with moderate-to-severe traumatic brain injury (msTBI). It will be theoretically based, use objective measurement of PA as a primary outcome, and incorporate varied types and amounts of home- and neighborhood-based PA and ways to reduce sedentary behavior, according to participant preferences. Moreover, using a 2-phase design as described below, the investigators will test a method for enhancing longer-term gains in PA using mobile technology, in addition to gains acquired during the first phase of intervention.

Trial design. Participants will undergo baseline testing (T1) and will then be randomized 1:1 to either immediate treatment in GetUp&Go (IT) or waitlist (WL) for 10 weeks. After testing for the primary outcome (T2), the waitlist group will receive GetUp&Go for 10 weeks followed by a T2b evaluation for that group. This phase is called the "A phase", for Acquisition.

Following completion of the GetUp&Go intervention, all participants-regardless of initial group allocation-will be randomized 1:1 to one of two conditions for an additional 10 weeks, the "Follow-Through" (FT) phase. Half of participants will be randomized to the RehaBot condition (RB), which provides continued use of the chatbot to support individualized PA plans, but with no further therapist contact. Participants in the No RehaBot (No RB) condition will not have access to the chatbot. The final evaluation, T3, will occur after the 10-week Follow-Through phase.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18
  • TBI (open or closed), sustained at least 6 months prior to enrollment, of at least complicated-mild/moderate severity as evidenced by loss or alteration of consciousness ≥ 30 minutes; and/or post-traumatic amnesia (PTA) ≥ 24 hours, not due to intoxication/sedation and documented prospectively from the injury; and/or positive neuroimaging findings consistent with TBI
  • Fully weight bearing on lower limbs and able to walk indoors and outdoors without the assistance of another person
  • Cognitively able to participate in treatment as judged by ability to travel independently within the community
  • Able to communicate adequately in English for participation in the treatment protocols
  • Informed consent given by participant

Exclusion criteria

  • Contraindications to increasing PA as judged by study physician, using an exam based on published screening tools
  • Medical or psychiatric instability, including current psychosis or severe uncontrolled substance misuse, as assessed using items from the SCID/MINI/ASSIST, or suicidal ideation with intent or plan, as assessed by the Columbia-Suicide Severity Rating Scale, screening version
  • Significant physical or intellectual disability predating the TBI
  • Neurodegenerative disorder, e.g., Parkinson's disease
  • Insufficiently inactive, i.e., reporting > 23 weekly moderate/vigorous activity units on the Godin Leisure-Time Exercise Questionnaire
  • Planned surgery or other hospitalization during the succeeding 9 months
  • Physical or sensory disability (e.g., blindness; severe bimanual incoordination) that prevents use of a smartphone

Treatment and study plan

GetUp&Go

Behavioral

A behavioral treatment combining personalized activity planning and a mobile health application for supporting adherence to activity plans.

GetUp&Go with 10-Week Delay

Behavioral

No assigned treatment during the waitlist phase. Participants in the WL group will be offered the GetUp&Go intervention, which combines personalized activity planning and a mobile health application, after collection of the primary outcome measure.

Primary outcomes

  1. Average activity counts/minute

    Time frame: Baseline

    Actigraphy derived average activity counts/minute from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  2. Average activity counts/minute

    Time frame: 10 weeks after initial randomization

    Actigraphy derived average activity counts/minute from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  3. Average activity counts/minute

    Time frame: 10 weeks after completing GetUp&Go intervention

    Actigraphy derived average activity counts/minute from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

Secondary outcomes

  1. Percent (%) time sedentary

    Time frame: Baseline

    Actigraphy derived percent time sedentary from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  2. Percent (%) time sedentary

    Time frame: 10 weeks after initial randomization

    Actigraphy derived percent time sedentary from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  3. Percent (%) time sedentary

    Time frame: 10 weeks after completing GetUp&Go intervention

    Actigraphy derived percent time sedentary from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  4. Percent (%) time engaged in moderate-vigorous physical activity (MVPA)

    Time frame: Baseline

    Actigraphy derived percent time engaged in MVPA from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  5. Percent (%) time engaged in moderate-vigorous physical activity (MVPA)

    Time frame: 10 weeks after initial randomization

    Actigraphy derived percent time engaged in MVPA from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  6. Percent (%) time engaged in moderate-vigorous physical activity (MVPA)

    Time frame: 10 weeks after completing GetUp&Go intervention

    Actigraphy derived percent time engaged in MVPA from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  7. Average daily step count

    Time frame: Baseline

    Actigraphy derived average daily step count from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  8. Average daily step count

    Time frame: 10 weeks after initial randomization

    Actigraphy derived average daily step count from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  9. Average daily step count

    Time frame: 10 weeks after completing GetUp&Go intervention

    Actigraphy derived average daily step count from wrist-worn Actigraph GT3XP averaged over 4 consecutive-wear days over a 7-day period

  10. Self-reported PA

    Time frame: Baseline

    Physical Activity Scale for Individuals with Physical Disabilities (Scale: 0-100, where higher scores indicate a greater level of activity)

  11. Self-reported PA

    Time frame: 10 weeks after initial randomization

    Physical Activity Scale for Individuals with Physical Disabilities (Scale: 0-100, where higher scores indicate a greater level of activity)

  12. Self-reported PA

    Time frame: 10 weeks after completing GetUp&Go intervention

    Physical Activity Scale for Individuals with Physical Disabilities (Scale: 0-100, where higher scores indicate a greater level of activity)

  13. Emotional function

    Time frame: Baseline

    Brief Symptom Inventory-18 (Scale: 0-72, where higher scores indicate the presence of more psychiatric symptoms)

  14. Emotional function

    Time frame: 10 weeks after initial randomization

    Brief Symptom Inventory-18 (Scale: 0-72, where higher scores indicate the presence of more psychiatric symptoms)

  15. Emotional function

    Time frame: 10 weeks after completing GetUp&Go intervention

    Brief Symptom Inventory-18 (Scale: 0-72, where higher scores indicate the presence of more psychiatric symptoms)

  16. Fatigue

    Time frame: Baseline

    Fatigue Severity Scale Short Form (Scale: 9-63, where higher scores indicate greater fatigue)

  17. Fatigue

    Time frame: 10 weeks after initial randomization

    Fatigue Severity Scale Short Form (Scale: 9-63, where higher scores indicate greater fatigue)

  18. Fatigue

    Time frame: 10 weeks after completing GetUp&Go intervention

    Fatigue Severity Scale Short Form (Scale: 9-63, where higher scores indicate greater fatigue)

  19. Sleep Quality

    Time frame: Baseline

    Pittsburgh Sleep Quality Index (Scale: 0-21, where higher scores indicate poorer sleep quality)

  20. Sleep Quality

    Time frame: 10 weeks after initial randomization

    Pittsburgh Sleep Quality Index (Scale: 0-21, where higher scores indicate poorer sleep quality)

  21. Sleep Quality

    Time frame: 10 weeks after completing GetUp&Go intervention

    Pittsburgh Sleep Quality Index (Scale: 0-21, where higher scores indicate poorer sleep quality)

  22. Subjective pain

    Time frame: Baseline

    Brief Pain Interference Scale (Scale: 6-30, where higher scores indicate greater pain interference)

  23. Subjective pain

    Time frame: 10 weeks after initial randomization

    Brief Pain Interference Scale (Scale: 6-30, where higher scores indicate greater pain interference)

  24. Subjective pain

    Time frame: 10 weeks after completing GetUp&Go intervention

    Brief Pain Interference Scale (Scale: 6-30, where higher scores indicate greater pain interference)

  25. Health-related Quality of Life

    Time frame: Baseline

    Quality of Life after Brain Injury Scale (Scale: 0-100, where higher scores indicate better quality of life)

  26. Health-related Quality of Life

    Time frame: 10 weeks after initial randomization

    Quality of Life after Brain Injury Scale (Scale: 0-100, where higher scores indicate better quality of life)

  27. Health-related Quality of Life

    Time frame: 10 weeks after completing GetUp&Go intervention

    Quality of Life after Brain Injury Scale (Scale: 0-100, where higher scores indicate better quality of life)

Study contacts

Contact information is provided by the study sponsor or research team.

Amanda Rabinowitz, PhD

CONTACT

[email protected]

215 663-6526

Lauren Krasucki, DPT, MPH

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Albert Einstein Healthcare Network

Other

Collaborators

  • National Institute on Disability, Independent Living, and Rehabilitation Research

Registry information

Official study title

GetUp&Go: A Randomized Controlled Trial of a Theory-Based Intervention to Enhance Physical Activity in Chronic, Moderate-Severe Traumatic Brain Injury

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Sep 8, 2023
Registry last updated
Mar 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.